IP Library › Granted Patent US 7,767,682
Granted Patent B2
US 7,767,682 · App. 11/817,523 · Granted Aug 3, 2010

Medicaments

Assignee: GlaxoSmithKline LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,767,682
App. No.
11/817,523
Granted
Aug 3, 2010
Kind
B2
Abstract

Methods of prevention or treatment of renal diseases or conditions associated with abnormal ion flux, in particular autosomal dominant polycystic kidney disease, with a modulator of human peroxisome proliferator activated receptor gamma.

Claims (1)

1. A method of treating autosomal dominant polycystic kidney disease in a human which comprises the administration of farglitazar or a pharmaceutically acceptable salt thereof to said human in need thereof.

Assignments (2)
CHANGE OF NAME Recorded May 4, 2010
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 024328/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2009
From: BLAZER-YOST, BONNIE L.
To: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Reel/Frame 022837/0870 →
Continuity (2)
Provisional Application 6065825500 · Mar 3, 2005
Related Publication 20080113996A1 · May 15, 2008